Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA injection sites in overactive bladder
NCT03523091Phase 4Terminated
- Sponsor
- Corewell Health
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in overactive bladder (OAB), sponsored by Corewell Health. Started Aug 2018; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03523091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523091.